

FORM PTO-1449 (Modified)

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENT (Use several sheets if necessary)

Attorney Docket No.: 15280-310100US

Application No.: 09/462,682

Applicant: FitzGerald *et al.*

Filing Date: January 10, 2000

Group: Unassigned

1645
Page 1

Reference Designation

U.S. PATENT DOCUMENTS

Examiner Initial	Document No.	Date	Name	Class	Sub-class	Filing Date (If Appropriate)
A	4,892,827	01/09/90	Pastan <i>et al.</i>			
B	5,082,927	01/21/92	Pastan <i>et al.</i>			
C	5,458,878	10/17/95	Pastan <i>et al.</i>			
D	5,602,095	02/11/97	Pastan <i>et al.</i>			
E	5,696,237	12/09/97	FitzGerald <i>et al.</i>			
F	5,705,156	01/06/98	Pastan <i>et al.</i>			
G	5,705,163	01/06/98	Pastan <i>et al.</i>			
H	5,854,044	12/29/98	Pastan <i>et al.</i>			
I	5,863,745	01/26/99	FitzGerald <i>et al.</i>			

FOREIGN PATENT DOCUMENTS

	Document No.	Date	Country	Class	Sub-class	Translation (Yes/No)
J	0 439 954 A2	12/24/90	Europe (Murphy)			
K	WO 98/20135	05/14/98	PCT (FitzGerald <i>et al.</i>)			
L	WO 97/13529	04/17/97	PCT (Pastan <i>et al.</i>)			

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

M	Brinkmann and Pastan, "Immunotoxins against cancer," <i>Biochimica et Biophysica Acta</i> , 1198:27-45 (1994)
N	Chaudhary, V.K. <i>et al.</i> , "Pseudomonas exotoxin contains a specific sequence at the carboxyl terminus that is required for cytotoxicity," <i>Proc. Natl. Acad. Sci. USA</i> , 87:308-312 (1990)
O	Cryz, Jr., S.J. <i>et al.</i> , "Human immunodeficiency virus-1 principal neutralizing domain peptide-toxin A conjugate vaccine," <i>Vaccine</i> , 13:67-71 (1995)
P	Cryz, Jr., S.J. <i>et al.</i> , "Safety and Immunogenicity of a Pseudomonas aeruginosa O-Polysaccharide Toxin A Conjugate Vaccine in Humans," <i>J. Clin. Invest.</i> , 80:51-56 (1987)
Q	Cryz, Jr., S.J. <i>et al.</i> , "Safety and Immunogenicity of <i>Escherichia coli</i> O18 O-Specific Polysaccharide (O-PS)-Toxin and O-PS-Cholera Toxin Conjugate Vaccines in Humans," <i>J. Infectious Diseases</i> , 163:1040-1045 (1990)
R	FitzGerald, D.J. <i>et al.</i> , "Characterization of V3 Loop-Pseudomonas Exotoxin Chimeras," <i>J. of Biol. Chem.</i> , 273(16):9951-9958 (1998)
S	Lukac, M. <i>et al.</i> , "Toxoid of <i>Pseudomonas aeruginosa</i> Exotoxin A Generated by Deletion of an Active-Site Residue," <i>Infection and Immunity</i> , 56(12):3095-3098 (1988)
T	Que, J.U. <i>et al.</i> , "Effect of Carrier Selection on Immunogenicity of Protein Conjugate Vaccines against <i>Plasmodium falciparum</i> Circumsporozoites," <i>Infection and Immunity</i> , 56:2645-2649 (1988)
U	Reiter <i>et al.</i> , "Engineering antibody Fv fragments for cancer detection and therapy: Disulfide-stabilized Fv fragments," <i>Nature Biotechnology</i> , 14:1239-1245 (1996)
V	Backstrom, M. <i>et al.</i> , "Insertion of a HIV-1-neutralizing epitope in a surface-exposed internal region of the cholera toxin B-subunit," <i>Gene</i> , 149:211-217 (1994)

8087 12/01

FORM PTO-1449 (Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Attorney Docket No.: 15280-310100US	Application No.: 09/462,682
		Applicant: FitzGerald <i>et al.</i>	
		Filing Date: January 10, 2000	Group: Unassigned <i>KO45</i>
<i>PP</i> W	Berman, P.W. <i>et al.</i> , "Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160," <i>Nature</i> , 345 :622-625 (1990)		
X	Eaton, A.M. <i>et al.</i> , "An Anti-gp41 Human Monoclonal Antibody That Enhances HIV-1 Infection in the Absence of Complement," <i>Aids Res. Hum. Retroviruses</i> , 10 :13-18(1994)		
Y	Emini, E.A. <i>et al.</i> , "Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody," <i>Nature</i> , 355 :728-730 (1992)		
Z	Evans, D.J. <i>et al.</i> , "An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies," <i>Nature</i> , 339 :385-388 (1989)		
AA	Fontenot, J.D. <i>et al.</i> , "Human immunodeficiency virus (HIV) antigens: Structure and serology of multivalent human mucin MUC1-HIV V3 chimeric proteins," <i>Proc. Natl. Acad. Sci. USA</i> , 92 :315-319 (1995)		
BB	Javaherian, K. <i>et al.</i> , "Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein," <i>Proc. Natl. Acad. Sci. USA</i> , 86 :6768-6772 (1989)		
CC	Kovacs, J.A. <i>et al.</i> , "Induction of Humoral and Cell-mediated Anti-Human Immunodeficiency Virus (HIV) Responses in HIV Sero-negative Volunteers by Immunization with Recombinant gp160," <i>J. Clin. Invest.</i> , 92 :919-928 (1993)		
DD	Mitchell, W.M. <i>et al.</i> , "Antibodies to the putative SIV infection-enhancing domain diminish beneficial effects of an SIV gp160 vaccine in rhesus macaques," <i>Aids</i> , 9 :27-34 (1995)		
EE	Montefiori, D.C. <i>et al.</i> , "Neutralizing and Infection-Enhancing Antibody Responses to Human Immunodeficiency Virus Type 1 in Long-Term Nonprogressors," <i>J. Infect. Dis.</i> , 173 :60-67 (1996)		
FF	Rusche, J.R. <i>et al.</i> , "Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120," <i>Proc. Natl. Acad. Sci. USA</i> , 85 :3198-3202 (1988)		
GG	Steimer, K.S. <i>et al.</i> , "Neutralization of Divergent HIV-1 Isolates by Conformation-Dependent Human Antibodies to Gp120," <i>Science</i> , 254 :105-108 (1991)		
HH	Toth, F.D. <i>et al.</i> , "Antibody-dependent enhancement of HIV-1 infection in human term syncytiotrophoblast cells cultured <i>in vitro</i> ," <i>Clin. Exp. Immunol.</i> , 96 :389-394 (1994)		
II	Wang, C.Y. <i>et al.</i> , "Long-Term High-Titer Neutralizing Activity Induced by Octameric Synthetic HIV-1 Antigen," <i>Science</i> , 254 :285-288 (1991)		
<i>PP</i> JJ	White-Scharf, M.E. <i>et al.</i> , "Broadly Neutralizing Monoclonal Antibodies to the V3 Region of HIV-1 Can Be Elicited by Peptide Immunization," <i>Virology</i> , 192 :197-206 (1993)		
EXAMINER	<i>PP</i> JJ		DATE CONSIDERED <i>12/01</i>

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.